At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ATNF 180 Life Sciences Corp
Pre-Market Trading 11-22 05:36:23 EST
2.28
-0.06
-2.56%
High2.45
Low2.21
Vol108.85K
Open2.35
D1 Closing2.34
Amplitude10.26%
Mkt Cap4.51M
Tradable Cap4.19M
Total Shares1.98M
T/O253.55K
T/O Rate5.92%
Tradable Shares1.84M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
BRIEF-180 Life Sciences Corp Files For Offering Of Up To 1.9 Million Shares By The Selling Stockholder - SEC Filing
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.